The goal of this clinical trial is to learn if pulse (pea) protein works similar to animal (whey) protein in protein bars consumed by healthy adults. The main questions it aims to answer are: What are the differences in taste and tolerance profiles between pea and whey proteins? What metabolic and immune changes do participants experience while eating them? What gastrointestinal microbiome shifts can be observed in these participants? How incorporation and complexation of polyphenols with these proteins changes the study outcomes? Participants will: Consume 1 protein bar with whey protein, pea protein, pea protein with complexed polyphenols, or pea protein with free polyphenols every day for 2 months. Visit the study site at baseline and end of study for checkups and tests. Fill dietary, food acceptance, gastrointestinal tolerance, and global health questionnaires.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
72
Whey protein bar
Pea protein bar
Pea protein with complexed polyphenols bar
Pea protein with free polyphenols bar
Plants for Human Health Institute
Kannapolis, North Carolina, United States
Taste
Participants will report taste of the protein bars using a 9-point hedonic scale scored from 1 (dislike extremely) to 9 (like extremely) in a Food Acceptance Questionnaire (FAQ)
Time frame: At baseline and after 2 months (end of study)
Gastrointestinal tolerance
Gastrointestinal tolerance will be assessed using the Gastrointestinal Tolerability Questionnaire (GTQ) scored on the scale of 0 (absent), 1 (mild), 2 (moderate), or 3 (severe)
Time frame: At baseline and after 2 months (end of study)
Perceived health
Overall perceived health will be monitored using self-reported wellness status as determined by PROMIS Global-10 questionnaire scored into a physical and mental health components on the scale of 1 (poor), 2 (fair), 3 (good), 4 (very good), or 5 (excellent).
Time frame: At baseline and after 2 months (end of study)
Fasting insulin
Blood
Time frame: At baseline and after 2 months (end of study)
Fasting glucose
Blood
Time frame: At baseline and after 2 months (end of study)
Glycosylated HbA1C
Blood
Time frame: At baseline and after 2 months (end of study)
triglycerides
Blood
Time frame: At baseline and after 2 months (end of study)
Cholesterol
Blood
Time frame: At baseline and after 2 months (end of study)
Homeostatic Model Assessment of Insulin Resistance
The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) will be calculated using fasting glucose (FG) and fasting insulin (FI) levels to evaluate insulin sensitivity as (FG×FI)/22.5.
Time frame: At baseline and after 2 months (end of study)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.